Factor VIII gene inversions in severe hemophilia A: results of an international consortium study.

نویسندگان

  • S E Antonarakis
  • J P Rossiter
  • M Young
  • J Horst
  • P de Moerloose
  • S S Sommer
  • R P Ketterling
  • H H Kazazian
  • C Négrier
  • C Vinciguerra
  • J Gitschier
  • M Goossens
  • E Girodon
  • N Ghanem
  • F Plassa
  • J M Lavergne
  • M Vidaud
  • J M Costa
  • Y Laurian
  • S W Lin
  • S R Lin
  • M C Shen
  • D Lillicrap
  • S A Taylor
  • S Windsor
  • S V Valleix
  • K Nafa
  • Y Sultan
  • M Delpech
  • C L Vnencak-Jones
  • J A Phillips
  • R C Ljung
  • E Koumbarelis
  • A Gialeraki
  • T Mandalaki
  • P V Jenkins
  • P W Collins
  • K J Pasi
  • A Goodeve
  • I Peake
  • F E Preston
  • M Schwartz
  • E Scheibel
  • J Ingerslev
  • D N Cooper
  • D S Millar
  • V V Kakkar
  • F Giannelli
  • J A Naylor
  • E F Tizzano
  • M Baiget
  • M Domenech
  • C Altisent
  • J Tusell
  • M Beneyto
  • J I Lorenzo
  • C Gaucher
  • C Mazurier
  • K Peerlinck
  • G Matthijs
  • J J Cassiman
  • J Vermylen
  • P G Mori
  • M Acquila
  • D Caprino
  • H Inaba
چکیده

Twenty-two molecular diagnostic laboratories from 14 countries participated in a consortium study to estimate the impact of Factor VIII gene inversions in severe hemophilia A. A total of 2,093 patients with severe hemophilia A were studied; of those, 740 (35%) had a type 1 (distal) factor VIII inversion, and 140 (7%) showed a type 2 (proximal) inversion. In 25 cases, the molecular analysis showed additional abnormal or polymorphic patterns. Ninety-eight percent of 532 mothers of patients with inversions were carriers of the abnormal factor VIII gene; when only mothers of nonfamilial cases were studied, 9 de novo inversions in maternal germ cells were observed among 225 cases (approximately 1 de novo maternal origin of the inversion in 25 mothers of sporadic cases). When the maternal grandparental origin was examined, the inversions occurred de novo in male germ cells in 69 cases and female germ cells in 1 case. The presence of factor VIII inversions is not a major predisposing factor for the development of factor VIII inhibitors; however, slightly more patients with severe hemophilia A and factor VIII inversions develop inhibitors (130 of 642 [20%]) than patients with severe hemophilia A without inversions (131 of 821 [16%]).

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Genotyping of Intron 22 and Intron 1 Inversions of Factor VIII Gene Using an Inverse-Shifting PCR Method in an Iranian Family with Severe Haemophilia A

Abstract Background: Haemophilia A (HA) is an X-linked bleeding disorder caused by the absence or reduced activity of coagulation factor VIII (FVIII). Coagulation factors are a group of related proteins that are essential for the formation of blood clots. The aim of this study was to genotype the coagulation factor VIII gene mutations using Inverse Shifting PCR (IS-PCR) in an Iranian family ...

متن کامل

Detection of Factor VIII Inhibitors in Hemophilia A Patients

Background: Factor VIII administration to hemophilia A patients results in an immune response (inhibitor formation) which significantly complicates the therapy. The present study was performed to determine the prevalence of inhibitor development in hemophilia A patients receiving recombinant factor VIII therapy. Materials and Methods: This was an observational descriptive study. Clotting fac...

متن کامل

Analysis of intron 22 inversions of the factor VIII gene in severe hemophilia A: implications for genetic counseling.

Intrachromosomal recombinations involving F8A, in intron 22 of the factor VIII gene, and one of two homologous regions 500 kb 5' of the factor VIII gene result in large inversions of DNA at the tip of the X chromosome. The gene is disrupted, causing severe hemophilia A. Two inversions are possible, distal and proximal, depending on which homologous region is involved in the recombination event....

متن کامل

Rituximab for Treatment of Hemophilia A with High-Responder Inhibitors

Background: The development of inhibitors is a complication factor replacement therapy in hereditary factor VIII deficiency. Several management options are available for the treatment of inhibitor. Rituximab, a monoclonal antibody against CD20, reduces inhibitor level in rare bleeding disorders. The aim of this study was to evaluate the effectiveness of rituximab in lowering or eliminating the ...

متن کامل

Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A.

The aim of the Malmö International Brother Study (MIBS) is to evaluate host genetic factors associated with the development of inhibitory antibodies in patients with hemophilia. Factor VIII gene mutations and genetic polymorphisms of the IL1beta, IL4, and IL10 genes, known to influence antibody production in autoimmune diseases, were analyzed in 164 patients (124 with severe, 26 with moderate, ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • Blood

دوره 86 6  شماره 

صفحات  -

تاریخ انتشار 1995